5nance5nance
5nance5nance
HomeScreens
LOGINGET FREE ACCOUNT

Pfizer Ltd.

•
pfizerltd.co.inBSE: 500680NSE: PFIZER
Market Cap₹ 19,083 Cr.
Current Price
High / Low₹ 5,578 / 4,158
Stock P/E26.0
Book Value₹ 963
Price to Book5.14
Dividend Yield1.80 %
ROCE23.4 %
ROE17.2 %
Face Value₹ 10

Add ratio to table

ABOUT

KEY POINTS

Revenue Breakup Mar 2013 • Pharmaceuticals: 87.2% • Others: 12.8%

AI Sector View

AI GENERATED

Healthcare

Buy

This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.

Confidence
50%
View full sector analysis →

PROS

  • Company is almost debt free
  • Company has a healthy return on capital (ROCE) of 24.0%
  • Strong cash generation - operating cash flow backs reported profits (CFO/PAT 0.92x)
  • Company has been maintaining a healthy dividend payout of 47.5%
  • Company comfortably covers its interest (103.0x coverage)
  • Company has a consistent dividend-paying track record

CONS

  • Recent results are weak - TTM profit is down 12.7% versus prior year
  • Company has delivered a poor sales growth of 2.4% over past five years
  • Recurring exceptional / one-off items are inflating headline profit
  • Company has delivered a poor profit growth of 7.7% over past five years
  • Stock is trading at 5.1x its book value

* The pros and cons are machine generated based on quantitative rules.

Peer comparison

HealthcareHealthcarePharmaceuticals & Drugs
Part ofNIFTY SMLCAP 250NIFTY 500NIFTY TOTAL MKT
S.No.Name
1.SUNPHARMA1868.5037.06448315.740.862901.2326.5315299.8810.9819.1128.81
2.DIVISLAB9482.7586.06251737.220.32902.0065.503080.0027.8021.5140.75
3.TORNTPHARM4931.9086.01187593.620.77566.003.284921.0057.3219.2733.81
4.ZYDUSLIFE1129.0024.95112618.180.09990.20-34.908017.0023.9721.3924.54
5.CIPLA1368.0032.79110515.040.95785.55-39.187119.284.1316.0016.73
6.LAURUSLABS1933.2595.54104455.860.10362.07123.942026.3129.1018.2031.50
7.AUROPHARMA1690.0026.1997238.860.241032.0325.229150.3517.4412.7620.54
8.LUPIN2092.0017.3095660.020.861416.9816.018276.8934.2828.8629.59
9.DRREDDY1143.2029.6195420.610.70435.60-69.108099.80-5.2113.7510.63
10.MANKIND2266.0045.8293596.020.04574.0929.124030.5912.8913.2426.30
11.GLENMARK2439.5538.2968850.120.10482.83927.884018.4831.3520.3520.03
12.PFIZER4171.35139.1719082.981.80204.476.63653.178.3123.3937.90
Detailed Comparison with:

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
531575540547563589538592603642645629653
421393387357385399392364393412417393421
Operating Profit111183153189177189146227210230228236232
OPM %20.84%31.75%28.25%34.65%31.53%32.15%27.14%38.43%34.83%35.80%35.38%37.50%35.49%
333644754243432176742-205045
Interest3337222332221
Depreciation16151814151515161414141514
Profit before Tax126201176244203215172426260255192269277
Tax %25.62%25.71%26.12%26.65%25.62%26.43%26.00%22.28%26.12%25.98%26.11%25.67%26.10%
Net Profit94149130179151158128331192189142200204
20.4432.5628.4239.0932.9434.6127.8972.3441.9141.3231.0143.6844.69

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
1,9661,9692,0822,1522,2392,6112,4252,1932,2812,5202,570
1,6161,4681,5161,5791,5261,7751,6161,5581,5411,6151,644
Operating Profit350501566573712836809635740904926
OPM %17.81%25.43%27.17%26.62%31.82%32.02%33.36%28.97%32.45%35.89%36.03%
2321141671848163134188345139116
Interest21211151113158108
Depreciation63667110310911510662615858
Profit before Tax5175486606426697738247461,016976993
Tax %34.84%34.28%34.98%20.76%25.59%20.74%24.28%26.10%24.46%25.96%25.95%
Net Profit337360429509498613624551768722735
EPS73.6178.7093.78111.28108.77133.89136.38120.51167.78157.91—
Dividend Payout %27.17%25.41%23.99%296.54%32.18%26.14%51.33%29.04%98.34%47.50%—

COMPOUNDED SALES GROWTH

10 Years:
2%
5 Years:
2%
3 Years:
1%

COMPOUNDED PROFIT GROWTH

10 Years:
9%
5 Years:
8%
3 Years:
5%

STOCK PRICE CAGR

10 Years:
8%
5 Years:
-8%
3 Years:
2%
1 Year:
-20%

RETURN ON EQUITY

10 Years:
17%
5 Years:
19%
3 Years:
18%
Last Year:
17%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Corporate actions

2026

Jul 17

₹ 7.50

Rs.75.0000 per share(750%)Final Dividend

2025

Jul 9

₹ 13

Rs.130.0000 per share(1300%)Special Dividend

2025

Jul 9

₹ 3.50

2024

Aug 21

₹ 3.50

Rs.35.0000 per share(350%)Final Dividend

2023

Aug 11

₹ 0.50

Rs.5.0000 per share(50%)Special Dividend

2023

Aug 11

₹ 3.50

2022

Sep 19

₹ 3

Rs.30.0000 per share (300%) Special Interim Dividend

2022

Aug 18

₹ 3.50

Rs.35.0000 per share(350%)Dividend

2021

Aug 11

₹ 3

Rs.5.0000 per share(50%)Special Dividend

2021

Aug 11

₹ 0.50

2018

Aug 29

₹ 2

Rs.20.0000 per share(200%)Dividend

2017

Aug 22

₹ 0.50

Rs.5.0000 per share(50%)Special Dividend

2017

Aug 22

₹ 1.50

14/09/2017 Equity Rs.5.0000 per share(50%)Special Dividend

2016

Jun 27

₹ 1.50

Rs.15.0000 per share(150%)Dividend

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital46464646464646464646
2,3732,6372,9663,3502,3472,8193,1623,5504,1724,157
222915113096577046
Trade Payables388496436427284264217166152216
452509490491525595383356403385
Total Liabilities3,2613,6903,9404,4053,2523,8543,9034,1754,8424,850
867917854942865841749713724678
Capital Work in Progress41013180820
322297387431435449418434476473
000001430188193182
Cash & Bank1,5231,7721,9142,2201,1151,6431,8602,0472,8013,111
545703785812835777869794641386
Total Assets3,2613,6903,9404,4053,2523,8543,9034,1754,8424,850

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
512525335536631667658257660968
Cash from Investing-250-238351,530-469-575-3654-71-562
Cash from Financing-83-110-110-164-1,571-181-346-235-205-798
-3-17231,690-1,613-88-2675383-392

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026

Shareholding Pattern

Numbers in percentages

Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
63.9263.9263.9263.9263.9263.9263.9263.9263.92
3.223.542.742.182.402.602.712.811.65
15.8316.0316.8017.1017.2317.1117.0516.8917.80
Government0.000.000.000.000.000.000.000.000.00
17.0216.5016.5416.8016.4516.3716.3216.3716.63

Documents

Corporate disclosures, annual reports, credit ratings, and concall transcripts

2026-09-07
Outcome of Board Meeting

2026-09-07 - Please find enclosed outcome of the Board Meeting held today i.e., September 7, 2026.

2026-08-04
Copy of Newspaper Publication

2026-08-04 - Pfizer Limited has informed the Exchange about Copy of Newspaper Publication

2026-07-29
Shareholders meeting

2026-07-29 - Pfizer Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on July 28, 2026. Further, the company has informed the Exchange regarding voting results.

2026-07-28
Shareholders meeting

2026-07-28 - Pfizer Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on July 28, 2026

2026-07-28
Outcome of Board Meeting

2026-07-28 - Pfizer Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.

2026-07-27
Change in Director(s)

2026-07-27 - Pfizer Limited has informed the Exchange regarding Change in Director(s) of the company.

2026-07-17
News Verification

2026-07-17 - The Exchange has sought clarification from Pfizer Limited with respect to recent news item captioned Pfizer suspends Premarin vaginal cream in India, raising concerns over menopause care.. The response from the Company is attached.

2026-07-17
News Verification

2026-07-17 - The Exchange has sought clarification from Pfizer Limited with respect to recent news item captioned Pfizer suspends Premarin vaginal cream in India, raising concerns over menopause care.. The response from the Company is awaited.

2026-07-10
Certificate under SEBI (Depositories and Participants) Regulations, 2018

2026-07-10 - Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended June 30, 2026.

News

Recent coverage and analyst commentary for PFIZER

Loading news…

🤖

AI Stock Analyst

Pfizer Ltd.

🔒

Sign in to Chat with AI

Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.

✨ Sign In to Chat

Free 5nance Account

5nance5nance

Stock analysis and screening tool

5nanceAI © 2020-2026

Made with ❤️ in India.

Data provided by Accord Fintech

Terms & Privacy.

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nance5nance

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nanceAI © 2020-2026

Data provided by Accord Fintech

Made with ❤️ in India.

HomeScreens
Login